Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.
PROPERTIES OF SYNTHETIC PEPTIDES THAT IDENTIFY NEUTRALIZING EPITOPES ON THE HIV ENVELOPE GLYCOPROTEIN
Vaccines 87. Modern Approaches to New Vaccines: Prevention of AIDS and Other Viral, Bacterial, and Parasitic Diseases. Chanock RM et al, eds. New York, Cold Spring Harbor Laboratory, p. 250-5, 1987.. Unique Identifier : AIDSLINE ICDB/88647986 Kennedy RC; Kanda P; Dreesman GR; Eichberg JW; Chanh TC; Ho DD; Sparrow JT; Dept. of Virology and Immunology, Southwest Foundation for; Biomedical Res., San Antonio, TX 78284
Abstract:
Studies have demonstrated that the most immunogenic component of human immunodeficiency virus (HIV) in infected individuals is the envelope glycoprotein (gp160). The predicted amino acid sequences of gp160 have been deduced by cloning the envelope proteins of several HIV isolates. Comparison of the amino acid sequences from various isolates demonstrates areas of extreme variability within gp160. However, constant regions, where the amino acid sequence variability is minimal, are also present among different isolates. Synthetic peptides corresponding in amino acid sequence to regions of gp160 can be used to identify neutralizing antigenic determinants and also have a potential as viral vaccine candidates. Characteristics of two synthetic peptides are described that identify neutralizing epitopes on gp160. One of these synthetic peptides was used to immunize chimpanzees, which were subsequently challenged with infectious HIV. Data are discussed which indicate that HIV synthetic peptide-immunized chimpanzees, as well as control chimpanzees, developed an anti-p24 response 6 wk following infection. No infectious HIV could be isolated from lymphocytes of any of the chimpanzees. The first study utilizing chimpanzees to determine efficacy of a potential HIV vaccine candidate is described. Antibodies generated against gp120 peptides 503-532 and gp41 peptides 735-752 had the following characteristics: detect HIV envelope glycoproteins by radioimmunoprecipitation; detect HIV envelope glycoproteins by Western blot analysis; bind HIV in HTLV-III (human T-lymphotropic virus type III) and LAV (lymphadenopathy-associated virus) commercial enzyme immunoassays; bind psoralen-inactivated HIV NY-5 isolate; stain surface of HIV-infected human T cells studied by flow cytometry; and neutralize HIV isolates HTLV-IIIB and NY-5 infectivity in vitro. (12 Refs)
Keywords: Acquired Immunodeficiency Syndrome/*IMMUNOLOGY Amino Acid Sequence Animal Antibodies, Viral/*ANALYSIS Chimpansee troglodytes Epitopes/IMMUNOLOGY Human HIV/*IMMUNOLOGY *Neutralization Tests Peptides/*IMMUNOLOGY Retroviridae Proteins/IMMUNOLOGY Vaccines, Synthetic/IMMUNOLOGY Viral Envelope Proteins/*IMMUNOLOGY Viral Vaccines/IMMUNOLOGY MEETING PAPER
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.
